Arimidex Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

First clinical experience with CDK4/6 inhibitors in breast cancer therapy
Exp Ther Med. 2021 May;21(5):522. doi: 10.3892/etm.2021.9954. Epub 2021 Mar 22.ABSTRACTFor hormone receptor-positive, HER2-negative breast cancer patients with metastatic or advanced disease, therapy with CDK4/6 inhibitors in addition to aromatase inhibitors (AIs) or to the estrogen receptor (ER) downregulator fulvestrant has resulted in an additional therapy option and a longer progression-free survival. In the Gynecologic-Oncology Clinic, Diakonie-Klinikum Schwäbisch Hall, we followed and registered our initial clinical experience with CDK4/6 inhibitors, following the side effects and tumor response over two years since...
Source: Experimental and Therapeutic Medicine - April 5, 2021 Category: General Medicine Authors: Ionut Marcel Cobec Lavinia Moleriu Aurica Elisabeta Moatar Andreas Rempen Source Type: research

Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients
Mayo Clin Proc. 2021 Apr;96(4):1033-1040. doi: 10.1016/j.mayocp.2021.01.028.ABSTRACTBreast cancer remains the most common cancer in women in the United States. For certain women at high risk for breast cancer, endocrine therapy (ET) can greatly decrease the risk. Tools such as the Breast Cancer Risk Assessment Tool (or Gail Model) and the International Breast Cancer Intervention Study risk calculator are available to help identify women at increased risk for breast cancer. Physician awareness of family history, reproductive and lifestyle factors, dense breast tissue, and history of benign proliferative breast disease are i...
Source: Clinical Breast Cancer - April 5, 2021 Category: Cancer & Oncology Authors: Elizabeth A Gilman Sandhya Pruthi Erin W Hofstatter Dawn M Mussallem Source Type: research

Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients
Mayo Clin Proc. 2021 Apr;96(4):1033-1040. doi: 10.1016/j.mayocp.2021.01.028.ABSTRACTBreast cancer remains the most common cancer in women in the United States. For certain women at high risk for breast cancer, endocrine therapy (ET) can greatly decrease the risk. Tools such as the Breast Cancer Risk Assessment Tool (or Gail Model) and the International Breast Cancer Intervention Study risk calculator are available to help identify women at increased risk for breast cancer. Physician awareness of family history, reproductive and lifestyle factors, dense breast tissue, and history of benign proliferative breast disease are i...
Source: Clinical Genitourinary Cancer - April 5, 2021 Category: Cancer & Oncology Authors: Elizabeth A Gilman Sandhya Pruthi Erin W Hofstatter Dawn M Mussallem Source Type: research

GSE161830 Molecular profiling of 16 week aromatase inhibitor-treated post-menopausal breast tumors
Contributor : A K DunbierSeries Type : Expression profiling by arrayOrganism : Homo sapiensTo identify the effect of 16 weeks of neoadjuvant anastrozole treatment on gene expression profiles of oestrogen receptor positive breast tumours from post-menopausal patients. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 1, 2021 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

Breast Angiosarcoma with a Preoperative Diagnosis of Late Recurrence of Breast Cancer: A Case Report
We report a case of breast angiosarcoma with a preoperative diagnosis of late recurrence of breast cancer. A 78-year-old woman noticed a tumor in her right breast and visited our hospital. The patient had undergone breast-conserving surgery and axillary lymph node dissection from the right breast 12 years before the visit. The tumor was diagnosed as T4bN0M0, stage IIIB. Anastrozole was administered as postoperative adjuvant therapy for 5 years; the patient also received 50-Gy whole-breast radiation therapy after surgery. Physical examination during her visit revealed an elevated lesion with blue purpura around the nipple i...
Source: Case Reports in Oncology - March 29, 2021 Category: Cancer & Oncology Source Type: research

Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients
This article is protected by copyright. All rights reserved.PMID:33713359 | DOI:10.1002/jcph.1856 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 13, 2021 Category: Cancer & Oncology Authors: Yasong Lu Shu Yang Yu-Yun Ho Yan Ji Source Type: research

Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients
This article is protected by copyright. All rights reserved.PMID:33713359 | DOI:10.1002/jcph.1856 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - March 13, 2021 Category: Drugs & Pharmacology Authors: Yasong Lu Shu Yang Yu-Yun Ho Yan Ji Source Type: research

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
ConclusionsHigher BMI is associated with greater breast cancer risk in postmenopausal women at increased risk of the disease, but no effect was observed in premenopausal women. The lack of interaction between BMI and treatment group on breast cancer risk suggests women are likely to experience benefit from preventive therapy regardless of their BMI.Trial registration Both trials were registered [IBIS-I: ISRCTN91879928 on 24/02/2006, retrospectively registered (http://www.isrctn.com/ISRCTN91879928); IBIS-II: ISRCTN31488319 on 07/01/2005, retrospectively registered (http://www.isrctn.com/ISRCTN31488319)] (Source: Breast Canc...
Source: Breast Cancer Research and Treatment - March 3, 2021 Category: Cancer & Oncology Source Type: research